BRIEF—IONTAS and aTen agree terms for antibody collaboration

Antibody specialist IONTAS and fellow UK-based biotech aTen Therapeutics have entered into a strategic collaboration.

Under the terms of the deal, IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by aTen.

IONTAS chief exec John McCafferty said his firm would “apply its technologies to overcome limitations of other platforms,” such as in vivo technologies, “to generate therapeutic leads against pre-defined specification from aTen.”

aTen chairman Chris Wood said his firm had selected IONTAS due to its “technological expertise and proven track record of delivering antibodies to all its partners.”